Zhejiang Cheng Yi Pharmaceutical Past Earnings Performance
Past criteria checks 2/6
Zhejiang Cheng Yi Pharmaceutical has been growing earnings at an average annual rate of 3.9%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been declining at an average rate of 0.8% per year. Zhejiang Cheng Yi Pharmaceutical's return on equity is 13.3%, and it has net margins of 22.7%.
Key information
3.9%
Earnings growth rate
3.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -0.8% |
| Return on equity | 13.3% |
| Net Margin | 22.7% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Zhejiang Cheng Yi Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 733 | 166 | 290 | 49 |
| 30 Jun 24 | 707 | 149 | 278 | 47 |
| 31 Mar 24 | 677 | 156 | 255 | 51 |
| 31 Dec 23 | 672 | 163 | 248 | 47 |
| 30 Sep 23 | 638 | 173 | 248 | 45 |
| 30 Jun 23 | 658 | 187 | 257 | 42 |
| 31 Mar 23 | 643 | 172 | 263 | 41 |
| 31 Dec 22 | 655 | 162 | 270 | 44 |
| 30 Sep 22 | 646 | 155 | 258 | 45 |
| 30 Jun 22 | 654 | 157 | 263 | 45 |
| 31 Mar 22 | 682 | 154 | 274 | 43 |
| 31 Dec 21 | 694 | 171 | 281 | 40 |
| 30 Sep 21 | 770 | 181 | 327 | 38 |
| 30 Jun 21 | 786 | 180 | 348 | 37 |
| 31 Mar 21 | 778 | 186 | 354 | 35 |
| 31 Dec 20 | 758 | 165 | 346 | 32 |
| 30 Sep 20 | 694 | 135 | 334 | 33 |
| 30 Jun 20 | 672 | 126 | 316 | 32 |
| 31 Mar 20 | 687 | 132 | 325 | 25 |
| 31 Dec 19 | 681 | 131 | 319 | 30 |
| 30 Sep 19 | 645 | 125 | 292 | 30 |
| 30 Jun 19 | 633 | 120 | 275 | 27 |
| 31 Mar 19 | 569 | 103 | 225 | 30 |
| 31 Dec 18 | 546 | 97 | 210 | 26 |
| 30 Sep 18 | 514 | 95 | 164 | 29 |
| 30 Jun 18 | 444 | 84 | 130 | 25 |
| 31 Mar 18 | 382 | 73 | 106 | 19 |
| 31 Dec 17 | 341 | 69 | 83 | 13 |
| 30 Sep 17 | 335 | 69 | 88 | 0 |
| 30 Jun 17 | 318 | 65 | 78 | 0 |
| 31 Mar 17 | 333 | 71 | 78 | 0 |
| 31 Dec 16 | 321 | 68 | 82 | 0 |
| 31 Dec 15 | 317 | 58 | 91 | 0 |
| 31 Dec 14 | 320 | 54 | 89 | 0 |
| 31 Dec 13 | 266 | 36 | 67 | 0 |
Quality Earnings: 603811 has high quality earnings.
Growing Profit Margin: 603811's current net profit margins (22.7%) are lower than last year (27.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 603811's earnings have grown by 3.9% per year over the past 5 years.
Accelerating Growth: 603811's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 603811 had negative earnings growth (-4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).
Return on Equity
High ROE: 603811's Return on Equity (13.3%) is considered low.